Venus Remedies Ltd
NSE:VENUSREM

Watchlist Manager
Venus Remedies Ltd Logo
Venus Remedies Ltd
NSE:VENUSREM
Watchlist
Price: 721.6 INR 1.9% Market Closed
Market Cap: 9.6B INR
Section:
 

Relative Value

The Relative Value of one VENUSREM stock under the Base Case scenario is hidden INR. Compared to the current market price of 721.6 INR, Venus Remedies Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VENUSREM Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.4
P/S
P/S
Price to Sales
1.4
vs History
3
vs Industry
80
Median 3Y
0.7
Median 5Y
0.7
Industry
2.7
Forward
1.3
More Details
13.7
P/E
P/E
Price to Earnings
13.7
vs History
41
vs Industry
36
Median 3Y
14.3
Median 5Y
12.2
Industry
21.6
Forward
19.5
More Details
6.8
P/OCF
P/OCF
Price to OCF
6.8
vs History
58
vs Industry
45
Median 3Y
7.3
Median 5Y
7
Industry
16.9
More Details
8
P/FCFE
P/FCFE
Price to FCFE
8
vs History
74
vs Industry
31
Median 3Y
10.4
Median 5Y
10.9
Industry
22.9
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
3
vs Industry
66
Median 3Y
0.9
Median 5Y
0.9
Industry
2.3
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
7
vs Industry
86
Median 3Y
0.6
Median 5Y
0.6
Industry
3
Forward
1
More Details
2.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.5
vs History
14
vs Industry
81
Median 3Y
1.4
Median 5Y
1.5
Industry
5.6
More Details
8.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.4
vs History
9
vs Industry
45
Median 3Y
6.4
Median 5Y
5.9
Industry
13.4
Forward
8.4
More Details
11.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.2
vs History
63
vs Industry
37
Median 3Y
11.6
Median 5Y
11.6
Industry
16.7
More Details
5.2
EV/OCF
EV/OCF
Enterprise Value to OCF
5.2
vs History
63
vs Industry
49
Median 3Y
6.3
Median 5Y
6.3
Industry
16.1
More Details
6.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
6.8
vs History
69
vs Industry
35
Median 3Y
8.1
Median 5Y
8.1
Industry
18.9
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
3
vs Industry
69
Median 3Y
0.8
Median 5Y
0.8
Industry
2
More Details

Multiples Across Competitors

VENUSREM Competitors Multiples
Venus Remedies Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Venus Remedies Ltd
NSE:VENUSREM
9.6B INR 1.4 13.7 8.4 11.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Venus Remedies Ltd
NSE:VENUSREM
Average P/E: 23.6
13.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Venus Remedies Ltd
NSE:VENUSREM
Average EV/EBITDA: 400.7
8.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Venus Remedies Ltd
NSE:VENUSREM
Average EV/EBIT: 1 713.4
11.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
VENUSREM intrinsic value, competitors valuation, and company profile.
DCF Valuation
VENUSREM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VENUSREM stock valuation using valuation multiples.
Wall Street Estimates
VENUSREM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VENUSREM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.